Bender Robert & Associates
VRTX icon

Bender Robert & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Bender Robert & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.9M Buy
26,658
+355
+1% +$182K 2.66% 12
2026
Q2 		$13.1M Buy
26,303
+132
+0.5% +$58.5K 2.72% 12
2026
Q1 		$11.7M Sell
26,171
-292
-1% -$136K 2.8% 11
2025
Q4 		$12M Buy
26,463
+133
+0.5% +$57.3K 2.49% 12
2025
Q3 		$10.3M Sell
26,330
-382
-1% -$160K 2.23% 14
2025
Q2 		$11.9M Sell
26,712
-313
-1% -$144K 2.65% 10
2025
Q1 		$13.1M Sell
27,025
-281
-1% -$131K 3.31% 8
2024
Q4 		$11M Buy
27,306
+172
+0.6% +$79.7K 2.65% 12
2024
Q3 		$12.6M Buy
+27,134
New +$13M 2.68% 11
2024
Q2 		– Sell
-28,172
Closed -$12.2M – 84
2024
Q1 		$11.8M Sell
28,172
-378
-1% -$160K 2.76% 13
2023
Q4 		$11.6M Buy
28,550
+96
+0.3% +$35.5K 2.93% 11
2023
Q3 		$9.9M Buy
28,454
+47
+0.2% +$16.4K 2.89% 12
2023
Q2 		$10M Sell
28,407
-430
-1% -$145K 2.76% 11
2023
Q1 		$9.09M Sell
28,837
-22
-0.1% -$6.6K 2.81% 12
2022
Q4 		$8.33M Buy
28,859
+5
+0% +$1.52K 3.12% 9
2022
Q3 		$8.35M Buy
28,854
+683
+2% +$197K 3.24% 10
2022
Q2 		$7.94M Sell
28,171
-271
-1% -$72.5K 3.04% 12
2022
Q1 		$7.42M Sell
28,442
-1,668
-6% -$396K 2.11% 14
2021
Q4 		$5.46M Hold
30,110
– – 1.58% 16
2021
Q3 		$5.46M Sell
30,110
-273
-0.9% -$53.3K 1.56% 16
2021
Q2 		$6.13M Buy
30,383
+238
+0.8% +$49.8K 1.74% 15
2021
Q1 		$6.48M Buy
+30,145
New +$6.62M 2.08% 14

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Bender Robert & Associates's VRTX Position: Q3 2026 in Review

Bender Robert & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q3 2026, buying an estimated $182K and bringing the position to 26,658 shares worth $13.9M. The position accounts for 2.66% of the portfolio, ranked #12.

Bender Robert & Associates first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. 658 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Bender Robert & Associates held 26,658 shares of Vertex Pharmaceuticals worth $13.9M as of Q3 2026.
  • Bender Robert & Associates bought 355 Vertex Pharmaceuticals shares in Q3 2026, an estimated $182K.
  • Vertex Pharmaceuticals made up 2.66% of Bender Robert & Associates's portfolio in Q3 2026, its #12 holding.
  • Bender Robert & Associates first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • 658 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Bender Robert & Associates's 13F filing for Q3 2026, filed 21 Oct 2026.